Fig. 3

Anti-Ro52 concentration predicts decline in vital capacity. Lung function, expressed as percentage of predicted vital capacity (%pVC), decreases at a faster rate in patients with systemic sclerosis-associated interstitial lung disease and high anti-Ro52 levels (-0.03%pVC/year; 95% CI: -0.05 – -0.02; p =  < 0.001). Prediction model using mixed model regression equation including anti-Ro52 concentration, anti-Scl-70, disease subtype, and immunomodulator use, with time-interaction terms, and sex; 95% confidence intervals indicated by shaded ribbons